Correlation between Immature Platelet Fraction and Platelet Aggregation in Type 2 Diabetes Mellitus with Cardiovascular Complications

2021 ◽  
Vol 8 (8) ◽  
pp. 23-26
Author(s):  
Amanah Anindita ◽  
Dharma Lindarto ◽  
Herman Hariman

Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia that occurs due to abnormalities in insulin secretion, insulin action or both. Diabetes is a risk factor for cardiovascular disease and atherothrombosis is a common complication of diabetes. There are several markers that can be used to see and monitor changes in the thrombosis and coagulation processes in DM patients, including the platelet index, platelet aggregation and D-dimer. To determine the correlation between immature platelet fraction with platelet aggregation in type 2 diabetes mellitus with cardiovascular complications. This study used a cross-sectional design. A total of 30 people with type 2 diabetes mellitus with cardiovascular complications will be tested for IPF and Platelet aggregation. Of the 30 patients, the mean IPF was 5.83 ± 1.55 %. From the analysis of Correlation found a significant relationship between the value of IPF with Platelet aggregation on ADP 5 μM and ADP 10 μM (r = 0.68; p <0.05), (r = 0.73; p <0.05) in type 2 DM patients with cardiovascular complications. In type-2 diabetes mellitus, there is a decrease in platelet life time and increased platelet turnover resulting immature platelets that are more reactive, where it will be easier for atherothrombosis. Platelet aggregation is a process where platelets adhere to each other at the site of vascular injury, which serves for the formation of a hemostatic plug and thrombosis. There is a significant correlation between the value of IPF with platelet aggregation in patients with type 2 diabetes with cardiovascular complications. Keywords: IPF, Platelet Aggregation, Type-2 DM.

2021 ◽  
Vol 2 (1) ◽  
pp. 23-28
Author(s):  
Alexander Petra Sihite ◽  
I Gusti Ngurah Pramesemara ◽  
I Wayan Surudarma

Background: Type 2 diabetes mellitus is a metabolic disease that characterized by high blood sugar levels. This condition is often not noticed immediately and usually patient starting to realize it when complications have been occurred. A long-term complication of type 2 DM that occurred in men is erectile dysfunction (ED). ED is a condition when a person is unable to achieve or maintain an erection for sexual intercourse. One factor that influence the occurrence of ED and its severity in type 2 DM patients is the duration of the disease. Objective: The aim of this study was to determine the relationship of type 2 DM duration and the occurrence of ED. Methods: This study is an observational analytic cross-sectional study conducted at the Puskesmas (Public Health Center) Denpasar Barat I. The research data was obtained through medical record data and fill the International Index of Erectile Function (IIEF-5) questionnaire on 36 type 2 DM patients aged around 40-60 years. The statistical analysis used was Fisher's exact test. Results: The results showed that of the 36 samples, 19 (52.8%) samples had type 2 DM <24 months and 17 (47.2%) samples had type 2 DM >24 months. It was found that 5 (13.9%) samples did not experience ED while the rest experienced ED with different severity. There was a significant relationship between the type 2 DM duration and the occurrence of erectile dysfunction at Puskesmas Denpasar Barat I (p = 0.022). Conclusion: Study has found that type 2 DM patients with the longer duration (>24 months)  have a higher occurrence of ED and tended to be more severe compared to those with shorter duration (<24 months). Further studies should be performed with higher number of patients and more controlled risk factor so it will be more accurate in determining the relationship between the duration of type 2 DM and ED.


2017 ◽  
Vol 66 (4) ◽  
pp. 747-754 ◽  
Author(s):  
Oana Milas ◽  
Florica Gadalean ◽  
Adrian Vlad ◽  
Victor Dumitrascu ◽  
Cristina Gluhovschi ◽  
...  

MicroRNAs (miRNAs) are short non-coding RNA species that are important post-transcriptional regulators of gene expression. The aim of the study was to establish a potential explanation of podocyte damage and proximal tubule (PT) dysfunction induced by deregulated miRNAs expression in the course of type 2 diabetes mellitus (DM). A total of 68 patients with type 2 DM and 11 healthy subjects were enrolled in a cross-sectional study and assessed concerning urinary albumin:creatinine ratio (UACR), urinary N-acetyl-β-D-glucosamininidase (NAG), urinary kidney injury molecule-1, urinary nephrin, podocalyxin, synaptopodin, estimated glomerular filtration rate (eGFR), urinary miRNA21, miRNA124, and miRNA192. In univariable regression analysis, miRNA21, miRNA124, and miRNA192 correlated with urinary nephrin, synaptopodin, podocalyxin, NAG, KIM-1, UACR, and eGFR. Multivariable regression analysis yielded models in which miRNA192 correlated with synaptopodin, uNAG, and eGFR (R2=0.902; P<0.0001), miRNA124 correlated with synaptopodin, uNAG, UACR, and eGFR (R2=0.881; P<0.0001), whereas miRNA21 correlated with podocalyxin, uNAG, UACR, and eGFR (R2=0.882; P<0.0001). Urinary miRNA192 expression was downregulated, while urinary miRNA21 and miRNA124 expressions were upregulated. In patients with type 2 DM, there is an association between podocyte injury and PT dysfunction, and miRNA excretion, even in the normoalbuminuria stage. This observation documents a potential role of the urinary profiles of miRNA21, miRNA124, and miRNA192 in early DN. Despite their variability across the segments of the nephron, urinary miRNAs may be considered as a reliable tool for the identification of novel biomarkers in order to characterize the genetic pattern of podocyte damage and PT dysfunction in early DN of type 2 DM.


Author(s):  
Prashant P. Shivgunde ◽  
Shantanu R. Joshi ◽  
Archana D. Kodilkar

Background: Diabetes is a chronic metabolic disease which affects the quality of life. It leads to multiple complications due to metabolic involvement. Out of multiple drugs used to treat diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors are comparatively new drugs used for type-2-diabetes mellitus (DM) treatment. This study aimed to find out the drug utilization (DU) 90% and use of DPP-4 inhibitors in patients with type-2-DM.Methods: A prospective, cross-sectional, observational study was conducted at a private healthcare clinic of an endocrinologist in Nashik. Type-2-DM patients of both sexes were selected and a total of 199 patients were enrolled in the study. The consented patients were interviewed and prescription copies were collected. After studying them; statistical analysis was done and results and conclusions were drawn.Results: Out of total prescribed drugs, 58.77% of drugs were anti-diabetics. It was observed that the biguanides were most frequently (25.32%) prescribed while the least prescribed drugs were meglitinide analogues (0.08%). Most commonly utilized anti-diabetic found to be metformin. Vildagliptin 50 mg is the most commonly prescribed drug from DPP-4 inhibitors. Most of the drugs from the DPP-4 inhibitor group came under DU90%.Conclusions:DPP-4 inhibitors are showing wide acceptability by endocrinologists for type-2-DM management, according to this study. Performing repetitive drug utilization pattern study and circulation of standard treatment guidelines to practising physicians can be required. To emphasize the point on generic prescription, more awareness should be created. So that these can responses to further cost-effective and rational prescribing practices. 


2020 ◽  
Vol 2 ◽  
pp. 26-30
Author(s):  
Sangeetha Roslind ◽  
Kunnummal Muhammed ◽  
K. G. Sajeeth Kumar

Objectives: The objectives of the study were (1) to study the cutaneous manifestations in patients with type 2 diabetes mellitus (DM) in comparison to normal subjects and (2) to document the association between cutaneous manifestations and complications of DM. Materials and Methods: In this 1-year comparative cross-sectional study, 100 patients receiving treatment at the diabetic clinic of a tertiary center were evaluated for cutaneous manifestations and complications due to diabetes. The cutaneous features in diabetics were compared with that of normal controls. An attempt was made to find out any association between cutaneous features of DM and internal organ involvement due to diabetes. Results: Cutaneous manifestations were more frequent in patients with type 2 DM than normal controls. The most common manifestation in diabetics was fungal infection followed by bacterial infection. Diabetic dermopathy was found to have statistically significant association with nephropathy, retinopathy, and neuropathy due to type 2 DM. Limitations: Limited sample size and study confined to a tertiary referral center. Conclusions: Dermatology manifestations provide important clues of prognostic significance in type 2 DM.


Author(s):  
Krishan Kumar Meena ◽  
Praveen Sharma ◽  
Swati Srivastava ◽  
Uma Kumari Meena

Introduction: Diabetes mellitus (DM) is common metabolic disorder leading to various complications including micro-vascular complication. Diabetes and thyroid dysfunction can result in abnormalities of one another, as both are strongly implicated in cellular metabolism.  Aim of study was to establish any association between hypothyroidism and micro-vascular complications in patients of type 2 DM. Material and Methods: This Hospital based Cross sectional analytical Study was included 80 Euthyroid and 80 hypothyroid patients of type 2 DM. These patients were subjected to fundus examination (for retinopathy), urine for spot albumin and creatinine ratio and routine microscopy (for nephropathy), clinical examination and NCV (for neuropathy). Results: Age of patients ranged from 30 – 80 years. Most patients had duration of Diabetes > 5 years. Diabetic retinopathy was found in 15% Euthyroid and 37.5% Hypothyroid diabetics (p=0.002). Neuropathy was more in Hypothyroid (35%) as compared to Euthyroid (12.5%) patients (p=0.003). Prevalence of Nephropathy was also significantly more (p=0.011) in Hypothyroids (60%) as compared to Euthyroid (38.75%). Conclusion: Significant association was found between hypothyroidism and micro vascular complications in type 2 Diabetes mellitus. Screening of diabetics for thyroid functions is essential to reduce morbidity. Keywords: Diabetes, thyroid, retinopathy, neuropathy, nephropathy


2019 ◽  
pp. 105-110
Author(s):  
O. M. Chernatska ◽  
T. S. Mazur ◽  
N. V. Demikhova ◽  
O. M. Vlasenko ◽  
T. M. Rudenko ◽  
...  

The actual problem of internal medicine is the managemen of patients with comorbid pathology. Arterial hypertension (AH) is determined in about quarter of the population in the world. Moreover, the coexistence of AH and type 2 diabetes mellitus (DM) connected with the increased risk of cardiovascular complications (CVC) compared with patients with AH. In principle dyslipidemia is the common link between AH and type 2 DM, which need the correction. No doubt that reduction of atherogenic and increase of anti atherogenic lipoproteins is necessary for persons with comorbid pathology. The objective of our study was the assessment of atorvastatin treatment in patients with AH, diabetic nephropathy and type 2 DM. We obtained 96 patients with AH, diabetic nephropathy and type 2 DM (І group), 25 persons with AH (ІІ group), 15 conditionally healthy individuals. Persons had CVC in the past. For patients from the І and ІІ group CVC were defined accordingly (4,97 ± 0,20) years and (4,10 ± 0,05) years ago (P = 0,0291). The duration of AH is (8,1 ± 0,2) years for the І group and (8,90 ± 0,13) years for the ІІ group. The levels of lipid profile spectrum were determined according to the methods of W. T. Friedewald. The results of investigation were analyzed with the help of Microsoft Excel 2016. Correction of lipid profile spectrum is the important part of multipurpose treatment for persons with coexistent pathology. All patients were treated by atorvastatin (10−40 mg/day) during 6 months in a complex therapy. The target levels of general cholesterol during 6 months were presented in 30 persons (31.91 %), low density lipoproteids – in 10 persons (10.64 %), high density lipoproteids – in 26 persons (27.66 %), triglycerides – in 34 persons (36.17 %) among patients with AH, diabetic nephropathy and type 2 DM. In conclusion, it is advisable to prescribe atorvastatin (10–40 mg/day) for correction of dyslipidemia, reduction of proatherogenic orientation, prevention of atherosclerotic process manifestation and cardiovascular complications in patients with AH with diabetic nephropathy and type 2 diabetes mellitus.


2021 ◽  
Vol 3 (2) ◽  
pp. 83-89
Author(s):  
Linda Ramadhanti ◽  
Devi Etivia Purlinda

Type 2 diabetes mellitus accounts for about 90% of all diabetes cases worldwide. Type 2 DM is caused by the body's inability to respond well to insulin or called insulin resistance. Insulin resistance causes hyperglycemia and hyperinsulinemia which results in decreased uric acid excretion function in the kidney tubules, so that there will be an increase in uric acid in the blood or hyperuricemia. Type of research including descriptive with cross sectional approach. The examination was carried out at Dr. Adhyatma, MPH. The research respondents were 24 people, uric acid levels were examined with a TMS 50i Superior device. The data obtained is processed and presented in the form of diagrams and percentages. Type 2 DM respondents numbered 24 people. The highest hyperuricemia is based on the characteristics of the respondents, those are above 55 years old (25%), female sex (25%), high blood pressure (25%), and exercise activity 1x / day (21%). Of the 24 respondents, 14 people (58.3%) had normal uric acid levels and 10 people (41.6%) had hyperuricemia, with an average female uric acid value of 5.54 mg / dL and men of 6,48 mg / dL.


2019 ◽  
Vol 7 (5) ◽  
Author(s):  
Tri Prasetyorini ◽  
Karningsih Sudiro ◽  
Bagya Mujianto ◽  
Rus Martini

Introduction and Aims : Untransmitted diseases is the leading cause of death globally. Diabetes mellitus is one of the four priorities of untransmitted diseases. This disease is a chronic disease characterized by blood glucose levels that exceed normal values. High blood sugar levels (hyperglycemia) will cause various complications, one of which is chronic complications that can attack various organs such as eyes, kidneys, nerves and blood vessels. This study aims to find out the correlation between the results of the examination of HbA1c, urea and creatinine levels which is an indicator of complications of Chronic Kidney Failure in Type 2 DM patients. Methods : This research is a survey research using cross-sectional study design. The respondents in this study are Type 2 DM patients who filled out the questionnaire and examined levels of HbA1c, ureum, and creatinine. Analysis of the data performed by using the SPEARMEN test SPSS for Windows 17. Result : The result of the SPEARMEN analysis is p = 0,016 (p < 0.05) which means there is a relationship between the levels of HbA1c with age of respondent. Meanwhile, p = 0,84 (p>0,05) which means there is no relationship between HbA1c levels of type 2 DM with urea levels of type 2 DM patients. While, there is no relationship between HbA1c levels of type 2 DM with creatinine levels of type 2 DM with p = 0.693 (p > 0,05). Conclusions : There is a correlation between HbA1c levels of type 2 diabetes mellitus with the age of the respondent, but there is no correlation between HbA1c levels of type 2 diabetes mellitus with ureum levels of type 2 diabetes mellitus and there is no correlation between HbA1c levels with Creatinine levels of  type 2 diabetes mellitus patients.


2021 ◽  
Author(s):  
Manal M. Alem

Abstract BackgroundType 2 diabetes mellitus (DM), gout, and asymptomatic hyperuricemia are inter-connected pathologies. Glycemic control (GC), involving a range of treatments is central to the management of DM, whereas allopurinol continues to be the most widely recommended urate lowering agent. Allopurinol has been shown to possess anti-oxidant properties: this study explores the favorable potential effect of allopurinol on glucose homeostasis.MethodsThis is an observational study with a cross-sectional design performed on patients with type 2 diabetes mellitus (DM), recruited from centers in Saudi Arabia. Patients were divided into two groups; allopurinol users; (for gout or asymptomatic hyperuricemia) and matching control patients. Patient demographics, co-morbid conditions, biochemical tests, and pharmacological treatments were extracted from electronic records to investigate the effect of allopurinol therapy on Glycemic control (GC), as assessed by glycated haemoglobin (HbA1c as primary endpoint), and on parameters of glycaemic variability (GV) (secondary endpoints).ResultsA total of 194 patients with type 2 DM were recruited (97 in both groups). The two groups were matched for age and sex: mean age: 59.4 years, 73% males in the allopurinol group vs 59.6 years, 73% males in the control group. Allopurinol, daily dose 100 mg, was prescribed for 77% of the patients, with median duration of 39.5 months treatment. HbA1c values were; 6.90% (6.20, 7.80) in the allopurinol group vs 7.30% (6.60, 8.40) in the control group (P=0.010). Parameters of GV were calculated from 3 consecutive fasting blood sugar (FBS) readings: variability independent of the mean (VIM) was 0.140 in the allopurinol group vs 0.987 in the control group (P<0.001).ConclusionConcomitant low-dose allopurinol therapy in patients with type 2 DM was associated with modest but significant improvements in GC and GV.


Sign in / Sign up

Export Citation Format

Share Document